Form 4: Cartesian Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, exercised stock options to acquire 9,000 shares of common stock at $3.23 per share.
Summary
- Christopher M. Jewell, the Chief Scientific Officer of Cartesian Therapeutics, exercised stock options on January 10, 2025.
- This transaction involved the acquisition of 9,000 shares of common stock at a price of $3.23 per share.
- Following the transaction, Jewell directly owns 62,490 shares of common stock.
- Jewell also holds options to purchase 67,432 additional shares of common stock.
- The options are exercisable, with a portion becoming fully exercisable by June 16, 2025.
- The options were initially converted from options to purchase Old Cartesian common stock following a merger on November 13, 2023, and later became exercisable for shares of the Issuer's Common Stock on April 8, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| November 13, 2023 | The Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ('Old Cartesian') in accordance with the terms of an Agreement and Plan of Merger. |
| April 8, 2024 | Options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock. |
| January 10, 2025 | Christopher M. Jewell exercised stock options to acquire 9,000 shares of common stock. |
| January 13, 2025 | Date of the signature of the report. |
| June 16, 2025 | Date when the option is fully exercisable. |
| January 15, 2033 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.